Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

denk pharma gmbh & co kg - amlodipinbesilat; hydroklortiazid; valsartan - filmdragerad tablett - 5 mg/160 mg/12,5 mg - amlodipinbesilat 6,94 mg aktiv substans; valsartan 160 mg aktiv substans; hydroklortiazid 12,5 mg aktiv substans

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

denk pharma gmbh & co kg - amlodipinbesilat; hydroklortiazid; valsartan - filmdragerad tablett - 10 mg/320 mg/25 mg - valsartan 320 mg aktiv substans; amlodipinbesilat 13,88 mg aktiv substans; hydroklortiazid 25 mg aktiv substans

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

alfred e tiefenbacher (gmbh & co. kg) - bilastin - tablett - 20 mg - bilastin 20 mg aktiv substans; mannitol hjälpämne

Europäische Union - Schwedisch - EMA (European Medicines Agency)

instituto grifols s.a. - humant normalt immunglobulin - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - immunförsvaret sera och immunglobuliner, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekursorcell lymfoblastisk leukemi-lymfom - antineoplastiska medel - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

2care4 aps - flutikasonpropionat; salmeterolxinafoat - inhalationspulver, avdelad dos - 50 mikrogram/500 mikrogram/dos - flutikasonpropionat 500 mikrog aktiv substans; salmeterolxinafoat 72,5 mikrog aktiv substans; laktosmonohydrat hjälpämne - salmeterol och flutikason

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

theramex ireland limited - risedronatnatrium - filmdragerad tablett - 35 mg - risedronatnatrium 35 mg aktiv substans; laktosmonohydrat hjälpämne - risedronsyra

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

orifarm ab - risedronatnatrium - filmdragerad tablett - 35 mg - laktosmonohydrat hjälpämne; risedronatnatrium 35 mg aktiv substans - risedronsyra

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

omnia läkemedel ab - risedronatnatrium - filmdragerad tablett - 35 mg - laktosmonohydrat hjälpämne; risedronatnatrium 35 mg aktiv substans - risedronsyra

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

theramex ireland limited - risedronatnatrium - filmdragerad tablett - 5 mg - risedronatnatrium 5 mg aktiv substans; laktosmonohydrat hjälpämne - risedronsyra